Skip to main content
Journal of General Internal Medicine logoLink to Journal of General Internal Medicine
editorial
. 2022 Sep 22;38(3):793–798. doi: 10.1007/s11606-022-07821-w

Are Current Guidelines Perpetuating Weight Stigma? A Weight-Skeptical Approach to the Care of Patients with Obesity

Scott Hagan 1,2,, Karin Nelson 1,2,3
PMCID: PMC9971382  PMID: 36138274

Abstract

Significant controversy exists regarding the evidence to support the clinical benefits and risks of weight loss interventions for individuals with obesity. United States Preventative Task Force (USPSTF) guidelines recommend weight loss for all individuals with obesity while weight-neutral models such as Health at Every Size promote weight inclusivity, focusing on body acceptance rather than weight loss. We discuss how lifestyle-based weight-centric paradigms, such as the USPSTF Guidelines, may increase weight stigma and weight cycling, and many of their purported clinical benefits are not supported by existing evidence. However, we also acknowledge the clear benefits of metabolic surgery in high-risk individuals, and the potential benefits for pharmacotherapy for obesity in selected patients. Herein we describe a weight-skeptical approach to the care of patients with obesity that aims to use available evidence to support patient-centered care.

KEY WORDS: obesity, weight loss, weight stigma

INTRODUCTION

How should primary care physicians and other clinicians counsel patients with obesity about the potential benefits and risks of weight loss? Because over half of US adults are classified as either overweight or obese according to body mass index (BMI),1,2 conversations about obesity are a routine part of primary care practice, yet much controversy exists regarding the evidence for strategies to guide these discussions. The 2018 United States Preventative Task Force (USPSTF) recommendations and the Health at Every Size (HAES) model of care present conflicting advice about the management of obesity. The USPSTF gives a grade B (moderate certainty of moderate net benefit) to their recommendation to offer lifestyle interventions that target at least 5% weight loss to adults with a BMI ≥ 30 kg/m2, or a BMI of 25–30 kg/m2 with hypertension, dyslipidemia, pre-diabetes, or diabetes.3 The primary clinical benefits cited to support these recommendations are a reduced incidence of type 2 diabetes in individuals with pre-diabetes, and the potential for clinically significant improvements in weight status with behavioral interventions.

In contrast, the HAES approach promotes weight inclusivity, which rejects the pathologizing of specific weights as inherently unhealthy.4 HAES treatment principles promote health improvement through enjoyable physical activity and eating for well-being without a focus on weight loss. Proponents of HAES cite improvements in quality of life, psychological well-being, eating behaviors, and aerobic capacity with weight-neutral interventions.5,6 The conflict between the weight-centric USPSTF recommendations and weight-neutral HAES principles should give pause to primary care clinicians who wish to practice patient-centered, evidence-based care. In this perspective, we describe what we term a “weight-skeptical” approach to the care of patients with obesity that offers an alternative to these guidelines by (1) acknowledging the potential harms of a weight-centric paradigm, (2) focusing on weight-neutral lifestyle and/or pharmacologic interventions when indicated for most patients with obesity, but also (3) accepting a role for weight loss interventions such as metabolic surgery and anti-obesity medications (AOM) in individuals at high risk for complications from obesity.

WHAT IS A “HEALTHY” WEIGHT?

In 1995, the World Health Organization (WHO) codified BMI as a screening index for obesity by defining a BMI 25–29.9 kg/m2 as overweight, and a BMI ≥ 30 kg/m2 as obesity.7 WHO further categorized obesity severity by classes I (30–34.9 kg/m2), II (35–39.9 kg/m2), and III (≥ 40 kg/m2).8 WHO BMI classes were created in part to emphasize the known association of increased mortality with a BMI both below and above the “normal” range (18.5–24.9 kg/m2).9,10 However, in the past half-century, control of cardiovascular risk factors such as hyperlipidemia and hypertension, primary drivers of mortality in individuals with obesity, has significantly improved across all BMI cohorts.11 Perhaps in part as a result, many modern cohort studies suggest that the lowest mortality-risk BMI, at least in studies primarily of European and North American populations, is in the overweight WHO classification, and that class I obesity does not confer significantly increased mortality risk.12,13 Class II and III obesity, however, continues to be associated with increased mortality risk in these studies.

Further, subsequent research has identified a wide diversity in health outcomes for different ethnic groups at similar BMIs.14,15 In a striking example from the UK, BMI significantly underestimated the risk for diabetes for many minority ethnic populations, especially those of South Asian descent, compared to White populations.16 In view of these differences, use of BMI cutoffs to identify individuals eligible for AOM or metabolic surgery might lead to substantial racial disparities in care for individuals who may benefit from weight loss interventions.

Cardiorespiratory fitness (CRF) and obesity-related comorbidities may significantly impact the mortality risk of an elevated BMI. Activity levels also have known strong associations with lower mortality,17,18 and increased physical activity improves CRF.19,20 Studies examining the relationship between BMI and mortality, when adjusted for CRF, have shown that the excess mortality risk of increased adiposity is greatly reduced or eliminated by having high CRF.2123 Metabolically healthy obesity (MHO), defined as having a BMI ≥ 30 kg/m2 with ≤ 1 cardiovascular risk factors of dyslipidemia, hypertension, or fasting hyperglycemia,24 is present in one- to two-thirds of adults with obesity.25,26 Adults with MHO have significantly decreased mortality compared to those with metabolically unhealthy obesity.27 Therefore, a person with obesity with high CRF and/or without metabolic comorbidities may have similar mortality to normal BMI, fit, metabolically healthy individuals.28

Finally, there are many effective interventions to manage obesity-related diseases without weight loss. In individuals with hypertension, weight-neutral dietary modifications such as the Dietary Approaches to Stop Hypertension diet lower blood pressure to a similar degree to weight-loss diets,2931 and exercise programs can reduce blood pressure independent of weight loss.32 Anti-hypertensives, when indicated, likely have a more pronounced blood pressure–lowering effect than these interventions.33 Weight loss diets for elevated LDL cholesterol in one randomized trial failed to lower LDL cholesterol,34 while statins,35 when indicated, and weight-neutral diets such as the Portfolio Diet36 have been shown to improve lipid profiles in hyperlipidemia. The DA Qing IGT and Diabetes Study showed similar reductions in diabetes incidence in those with prediabetes when comparing exercise alone to a weight loss diet,37 suggesting that exercise may be as effective as weight loss diets for diabetes prevention. Similar positive effects of exercise alone have been shown for glycemic control in individuals with type 2 diabetes.38 Healthy diets, physical activity, and pharmacotherapy can protect the health of persons with metabolic comorbidities of obesity without weight loss.

HOW EFFECTIVE ARE WEIGHT LOSS INTERVENTIONS?

Despite the rising prevalence of dieting in US adults with obesity,39,40 clinical trials of diet programs across the spectrum of macronutrient compositions consistently fail to produce clinically significant weight loss at 12 months for most individuals.41 Patients who are highly motivated to adhere to a strict diet and exercise program face the challenge of any significant weight loss attempt: adiposity stores are centrally regulated, and the body defends against weight loss.42 The mechanisms of this complex, long-term defense include metabolic adaptation, in which energy expenditure decreases more than expected from weight change alone,43,44 and increased hunger hormone signaling leading to an increased drive to eat.45 These defenses promote positive energy balance, leading to weight regain in most circumstances.

While weight loss diets are mostly ineffective, metabolic surgery is highly effective for long-term weight loss, resulting in an average of 22% weight loss at 20 years follow-up.46 The safety of these procedures has also greatly improved in the past 30 years with the advent of the laparoscopic technique and better guidelines for perioperative care for metabolic surgery.47,48 These procedures, however, remain generally reserved for patients with a BMI of 40 kg/m2, or 35 kg/m2 with comorbidities,48 and utilization in eligible patients remains exceptionally low in the USA (0.5%).47

Finally, the weight loss efficacy of AOM has substantially increased in the past decade since U.S. Food and Drug Administration approval of bupropion-naltrexone, liraglutide, phentermine-topiramate, and semaglutide. These therapies average 6–15% weight loss at 12 months, depending on the medication.4952 Promising additional AOM include tirzepatide53 and semaglutide-cagrilintide,54 for which early evidence suggests increased weight loss compared to semaglutide to a degree approaching metabolic surgery. However, until prescription drug coverage for novel AOM improves,55 these interventions are likely to be cost-prohibitive for most patients.

DOES WEIGHT LOSS REALLY IMPROVE HEALTH?

In preparation for the USPSTF 2018 recommendations, investigators prepared a systematic review of behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality. This review reported no improvement in mortality, cardiovascular outcomes, or health-related quality of life for intervention arms of behavioral and pharmacological weight loss and maintenance trials.56 For behavioral interventions, these findings are not surprising given that most subjects do not maintain 5% weight loss, the amount necessary to result in long-term clinical benefits for a variety of obesity-related comorbidities.57

While behavioral and pharmacologic interventions have not yet demonstrated improvement in most clinical outcomes, compelling evidence suggests that metabolic surgery in high-risk patients confers a substantial mortality benefit.58 However, the average BMI of the individuals enrolled in these studies was above 40 kg/m2. Therefore, it is unclear if the same health benefits would be evident in those with class I or class II obesity. As increasingly effective AOM develop with indications for class I and II obesity, studies of AOM must begin to assess health outcomes beyond weight loss itself. A promising upcoming example is SELECT, a randomized controlled trial of semaglutide for secondary prevention of cardiovascular disease in individuals with obesity and without diabetes.59

WHY RECOMMENDING WEIGHT LOSS DIETING MAY BE HARMFUL

Patients with obesity receiving health care in a weight-centric paradigm endorsed by the USPSTF may be at increased risk for weight stigma.60,61 When recommending diet and exercise with the goal of weight loss to individuals with obesity, most of whom have had unsuccessful weight loss attempts in the past, clinicians may be implying to these individuals that they simply need to try harder to lose weight, reenforcing a stereotype that individuals with obesity lack discipline and self-control. In surveys both of providers and patients, weight bias perpetrated by health care practitioners is common,6265 and can contribute to weight bias internalization (WBI), in which an individual is aware of their stigmatized identity and applies negative stereotypes (e.g., that individuals with obesity are lazy, lack self-control) to themselves. WBI is strongly associated with poor health outcomes such as worsened mental health, stress, health-related quality of life, and disordered eating,66 and over half of individuals with a BMI ≥ 30 kg/m2 in one survey had very high scores on an index of WBI.67 Identifying implicit and explicit weight bias in primary care settings and avoiding stigmatizing language is critical to improve the care of patients with obesity.63,68,69

Beyond the risk for promoting weight stigma, an additional harm of recommending dieting for weight loss is the risk for weight cycling, in which those who attempt diets repeatedly lose and regain weight. Weight cycling may lead to long-term weight gain, insulin resistance, dyslipidemia, and hypertension,39 and, in some secondary analyses of clinical trial data and prospective cohort studies, has been associated with increased mortality.7072 Especially in patients with a history of repeated weight loss and regain, clinicians should understand this risk.

A WEIGHT-SKEPTICAL APPROACH TO THE CARE OF PATIENTS WITH OBESITY

Table 1 summarizes the key principles of a weight-skeptical approach to the care of patients with obesity. Based on current evidence, we propose maintaining skepticism toward the treatment benefits of weight loss interventions, as they may be attenuated by the potential harms of weight stigma and weight cycling imposed by weight-centric strategies. Further, the potential clinical benefits of weight loss may depend on an individual’s underlying cardiorespiratory fitness and comorbidities, as well as the modality of treatment. Table 2 reviews several common patient scenarios, with suggested language for clinicians using a weight-skeptical approach to care.

Table 1.

A Weight-Skeptical Approach to the Care of Patients with Obesity

Topic area Key points
The use of screening indices for obesity

• Elevated BMI may not indicate “overweight” or confer health risks

• The risks of elevated BMI may vary substantially according to factors such as ethnicity, metabolic comorbidities, and cardiorespiratory fitness

Lifestyle interventions for weight loss

• Diets for weight loss are ineffective because the body regulates weight

• Weight cycling from chronic dieting attempts is likely harmful

• Exercise can greatly improve health even without weight loss

Weight stigma in healthcare settings

• Recommending dieting for weight loss to patients with unsuccessful past diet efforts may promote weight stigma and ignore scientific evidence by implying to patients that they just need to try harder to lose weight

• Health care–related weight stigma harms the mental and physical health of individuals with obesity

• Ask permission to discuss weight with patients, and respect the patient’s right to decline the discussion

• Clinicians should recognize and confront explicit and implicit weight bias in themselves and in their health systems

Managing the metabolic syndrome without weight loss

• Promoting enjoyable physical activity and healthy, weight-neutral diets is generally effective for treating obesity-related conditions

• Exercise programs significantly improve glycemic control in diabetes or prediabetes

• Weight-neutral diets and statins, when indicated, reduce LDL cholesterol more than weight loss diets

• The DASH diet and anti-hypertensive medications effectively lower blood pressure

The role of weight loss interventions beyond diet and exercise

• Patients with high-risk obesity (e.g., class II or III obesity with disabling obesity-related comorbidities) may benefit from AOM and/or metabolic surgery

• Remain open to broadening indications for AOM if more evidence accumulates for health benefits beyond weight loss itself

• Avoid stigmatizing language regarding the inherent superiority of lower body weight when introducing weight loss interventions to patients

• Respect the right for patients to decline AOM and surgery without judgment, and return to a weight-neutral approach to care

Table 2.

Common Patient Interactions with a Weight-Skeptical Approach

Clinical scenario Weight-skeptical clinician response*
35 year-old man with a BMI of 31 kg/m2 and hypertension would like to pursue lifestyle-based weight loss to manage a medical condition while you would like to recommend other treatment approaches.

General recommendations: practice shared-decision making while presenting weight-neutral, condition-specific strategies. A useful thought experiment is asking oneself, “How would I manage this condition for someone without obesity?” In this example, the DASH diet, an exercise program, and anti-hypertensive medications may be effective for blood pressure control.

• “There are good ways to lower your blood pressure without weight loss. Would it be okay if we discuss some other treatment options?”

• “I recommend taking this medication to control the blood pressure now, while you work towards changes to diet and activity levels to improve your blood pressure.”

A patient has tried a number of different diets without sustained weight loss, and asks for your opinion regarding the most effective diet for weight loss.

General recommendations: there is no evidence that diets of any particular macronutrient profile are significantly more effective for long-term weight loss.41 Ask the patient about their weight history, and counsel on the risks of weight cycling if their weight history suggests it. Consider shifting the conversation to healthy, weight-neutral diets, such as the DASH or Mediterranean diets.

• “I do not recommend a diet for weight loss, because no specific diet has been shown to be more effective.”

• “Weight loss diets can put stress on the body and may not improve your health. I recommend that we talk about other ways to improve your health.”

A patient feels frustrated that their efforts at diet and exercise have been unsuccessful. Example comment: “I don’t understand. I have been counting my calories and keeping up with my exercise program, but my weight just won’t budge.”

General recommendations: avoid medical jargon when explaining body weight regulation. Acknowledge the patient’s efforts to improve their health. Find ways to promote self-efficacy, such as focusing on diet quality rather than caloric restriction, and exercise for health rather than weight loss.

• “Your body might like the weight you are at.”

• “Your body is trying to defend against your hard work at trying to lose weight. If it is okay with you, I recommend that we talk about other strategies besides weight loss to protect your health.”

• “I think you can be healthy without losing weight.”

A 35-year-old woman with a BMI of 41 kg/m2 and insulin-dependent diabetes. This is a patient for whom you feel weight loss interventions may be beneficial.

General recommendations: Consider building rapport and trust through multiple visits before beginning discussions about weight. Avoid stigmatizing language69 and ask permission to begin a conversation about weight management. Review past weight loss interventions prior to providing recommendations. Use improvements in markers of medical comorbidities (e.g., reduction in insulin requirements or hemoglobin a1c), rather than a specific target weight as the goal of weight loss. If the patient declines AOM or metabolic surgery, return to a weight-neutral treatment approach.

• “Would it be okay with you if we talked about your weight?”

• “Lowering your weight might improve your health. If it is okay with you, I’d like to discuss some options that may help with weight management.”

*We recommend the UConn Rudd Center website (uconnruddcenter.org/research/weight-bias-stigma/healthcare-providers) which has numerous resources on reducing weight stigma in patient interactions

This framework allows a clinician to incorporate new evidence for the possible benefits of AOM or weight-neutral strategies in a likely future when highly effective AOM is broadly available, and more weight-neutral lifestyle programs are tested for their clinical benefits. Obesity treatment guidelines of the future may recommend against or make optional weight loss interventions for adults with class I or II obesity who have controlled cardiovascular risk factors and good CRF, while recommending AOM and/or metabolic surgery in patients as treatment options in patients with higher-risk obesity.

CONCLUSION

A weight-skeptical approach to the care of patients with obesity provides an alternative to strictly weight-centric or weight-neutral paradigms. It encourages clinicians to question the role of BMI in predicting health outcomes, and to acknowledge the lack of evidence for the long-term clinical benefits of lifestyle-based weight loss interventions for many adults with obesity. Critically, this model of care recognizes the potential harms of weight-centric treatment, such as the risk for weight bias and weight cycling. The impact of adopting such an approach is that a primary care clinician may often find themself steering away from recommendations for weight loss and toward weight-neutral interventions, while still offering AOM and metabolic surgery, when available and desired by the patient, to improve the health of patients at high risk for complications from obesity.

Declarations

Conflict of Interest

The authors declare that they do not have a conflict of interest.

Footnotes

Prior Presentations: None

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief. 2020(360):1-8. [PubMed]
  • 2.Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315(21):2284-2291. [DOI] [PMC free article] [PubMed]
  • 3.Curry SJ, Krist AH, Owens DK, et al. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(11):1163-1171. [DOI] [PubMed]
  • 4.Association for Size Diversity and Health HAES Principles. https://asdah.org/health-at-every-size-haes-approach/. Accessed 22 April 2022.
  • 5.Ulian MD, Aburad L, da Silva Oliveira MS, et al. Effects of health at every size® interventions on health-related outcomes of people with overweight and obesity: a systematic review. Obes Rev. 2018;19(12):1659-1666. [DOI] [PubMed]
  • 6.Dimitrov Ulian M, Pinto AJ, de Morais Sato P, et al. Effects of a new intervention based on the Health at Every Size approach for the management of obesity: The "Health and Wellness in Obesity" study. PLoS ONE. 2018;13(7):e0198401. [DOI] [PMC free article] [PubMed]
  • 7.Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1-452. [PubMed]
  • 8.Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253. [PubMed]
  • 9.Manson JE, Stampfer MJ, Hennekens CH, Willett WC. Body weight and longevity. A reassessment. JAMA. 1987;257(3):353-358. [PubMed]
  • 10.Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med. 1995;333(11):677-685. [DOI] [PubMed]
  • 11.Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA. 2005;293(15):1868-1874. [DOI] [PubMed]
  • 12.Afzal S, Tybjærg-Hansen A, Jensen GB, Nordestgaard BG. Change in body mass index associated with lowest mortality in Denmark, 1976-2013. JAMA. 2016;315(18):1989-1996. [DOI] [PubMed]
  • 13.Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309(1):71-82. [DOI] [PMC free article] [PubMed]
  • 14.Shai I, Jiang R, Manson JE, et al. Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. Diabetes Care. 2006;29(7):1585-1590. [DOI] [PubMed]
  • 15.Pan WH, Flegal KM, Chang HY, Yeh WT, Yeh CJ, Lee WC. Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. Am J Clin Nutr. 2004;79(1):31-39. [DOI] [PubMed]
  • 16.Caleyachetty R, Barber TM, Mohammed NI, et al. Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2021;9(7):419-426. [DOI] [PMC free article] [PubMed]
  • 17.Paluch AE, Gabriel KP, Fulton JE, et al. Steps per day and all-cause mortality in middle-aged adults in the coronary artery risk development in young adults study. JAMA Netw Open. 2021;4(9):e2124516. [DOI] [PMC free article] [PubMed]
  • 18.Moore SC, Patel AV, Matthews CE, et al. Leisure time physical activity of moderate to vigorous intensity and mortality: a large pooled cohort analysis. PLoS Med. 2012;9(11):e1001335. [DOI] [PMC free article] [PubMed]
  • 19.Oja P. Dose response between total volume of physical activity and health and fitness. Med Sci Sports Exerc. 2001;33(6 Suppl):S428-437; discussion S452-423. [DOI] [PubMed]
  • 20.Church TS, Earnest CP, Skinner JS, Blair SN. Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women with elevated blood pressure: a randomized controlled trial. JAMA. 2007;297(19):2081-2091. [DOI] [PubMed]
  • 21.Wei M, Kampert JB, Barlow CE, et al. Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men. JAMA. 1999;282(16):1547-1553. [DOI] [PubMed]
  • 22.Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med. 2004;351(26):2694-2703. [DOI] [PubMed]
  • 23.Gaesser GA, Angadi SS. Obesity treatment: Weight loss versus increasing fitness and physical activity for reducing health risks. iScience. 2021;24(10):102995. [DOI] [PMC free article] [PubMed]
  • 24.Lavie CJ, Laddu D, Arena R, Ortega FB, Alpert MA, Kushner RF. Reprint of: Healthy Weight and Obesity Prevention: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(23 Pt B):3027-3052. [DOI] [PubMed]
  • 25.Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008;168(15):1617-1624. [DOI] [PubMed]
  • 26.Caleyachetty R, Thomas GN, Toulis KA, et al. Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. J Am Coll Cardiol. 2017;70(12):1429-1437. [DOI] [PubMed]
  • 27.Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med. 2013;159(11):758-769. [DOI] [PubMed]
  • 28.Ortega FB, Lee DC, Katzmarzyk PT, et al. The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. Eur Heart J. 2013;34(5):389-397. [DOI] [PMC free article] [PubMed]
  • 29.Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336(16):1117-1124. [DOI] [PubMed]
  • 30.Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3-10. [DOI] [PubMed]
  • 31.Semlitsch T, Krenn C, Jeitler K, Berghold A, Horvath K, Siebenhofer A. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev. 2021;2(2):Cd008274. [DOI] [PMC free article] [PubMed]
  • 32.Dengel DR, Galecki AT, Hagberg JM, Pratley RE. The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glucose tolerance in older men. Am J Hypertens. 1998;11(12):1405-1412. [DOI] [PubMed]
  • 33.Wu J, Kraja AT, Oberman A, et al. A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens. 2005;18(7):935-942. [DOI] [PubMed]
  • 34.Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med. 1998;339(1):12-20. [DOI] [PubMed]
  • 35.Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81(5):582-587. [DOI] [PubMed]
  • 36.Jenkins DJ, Jones PJ, Lamarche B, et al. Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial. JAMA. 2011;306(8):831-839. [DOI] [PubMed]
  • 37.Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537-544. [DOI] [PubMed]
  • 38.Boulé NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286(10):1218-1227. [DOI] [PubMed]
  • 39.Montani JP, Schutz Y, Dulloo AG. Dieting and weight cycling as risk factors for cardiometabolic diseases: who is really at risk? Obes Rev. 2015;16 Suppl 1:7-18. [DOI] [PubMed]
  • 40.Martin CB, Herrick KA, Sarafrazi N, Ogden CL. Attempts to lose weight among adults in the United States, 2013-2016. NCHS Data Brief. 2018(313):1-8. [PubMed]
  • 41.Ge L, Sadeghirad B, Ball GDC, et al. Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials. BMJ. 2020;369:m696. [DOI] [PMC free article] [PubMed]
  • 42.McMinn JE, Baskin DG, Schwartz MW. Neuroendocrine mechanisms regulating food intake and body weight. Obes Rev. 2000;1(1):37-46. [DOI] [PubMed]
  • 43.Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med. 1995;332(10):621-628. [DOI] [PubMed]
  • 44.Fothergill E, Guo J, Howard L, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity (Silver Spring). 2016;24(8):1612-1619. [DOI] [PMC free article] [PubMed]
  • 45.Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604. [DOI] [PubMed]
  • 46.O'Brien PE, Hindle A, Brennan L, et al. Long-term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding. Obes Surg. 2019;29(1):3-14. [DOI] [PMC free article] [PubMed]
  • 47.Campos GM, Khoraki J, Browning MG, Pessoa BM, Mazzini GS, Wolfe L. Changes in utilization of bariatric surgery in the United States From 1993 to 2016. Ann Surg. 2020;271(2):201-209. [DOI] [PubMed]
  • 48.Mechanick JI, Apovian C, Brethauer S, et al. Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures - 2019 Update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Obesity (Silver Spring). 2020;28(4):O1-o58. [DOI] [PubMed]
  • 49.Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935-943. [DOI] [PMC free article] [PubMed]
  • 50.Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22. [DOI] [PubMed]
  • 51.Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352. [DOI] [PubMed]
  • 52.Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-1413. [DOI] [PMC free article] [PubMed]
  • 53.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. [DOI] [PubMed]
  • 54.Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748. [DOI] [PubMed]
  • 55.Gomez G, Stanford FC. US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity. Int J Obes (Lond). 2018;42(3):495-500. [DOI] [PMC free article] [PubMed]
  • 56.LeBlanc EL, Patnode CD, Webber EM, Redmond N, Rushkin M, O’Connor EA. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. In: Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018. [PubMed]
  • 57.Cefalu WT, Bray GA, Home PD, et al. Advances in the science, treatment, and prevention of the disease of obesity: reflections from a diabetes care editors' expert forum. Diabetes Care. 2015;38(8):1567-1582. [DOI] [PMC free article] [PubMed]
  • 58.Syn NL, Cummings DE, Wang LZ, et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants. Lancet. 2021;397(10287):1830-1841. [DOI] [PubMed]
  • 59.Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J. 2020;229:61-69. [DOI] [PubMed]
  • 60.Tylka TL, Annunziato RA, Burgard D, et al. The weight-inclusive versus weight-normative approach to health: evaluating the evidence for prioritizing well-being over weight loss. J Obes. 2014;2014:983495. [DOI] [PMC free article] [PubMed]
  • 61.Hagan S. E66.01 and our culture of shame. N Engl J Med. 2021;385(25):2307-2309. [DOI] [PubMed]
  • 62.Puhl RM, Brownell KD. Confronting and coping with weight stigma: an investigation of overweight and obese adults. Obesity (Silver Spring). 2006;14(10):1802-1815. [DOI] [PubMed]
  • 63.Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. Nat Med. 2020;26(4):485-497. [DOI] [PMC free article] [PubMed]
  • 64.Schwartz MB, Chambliss HO, Brownell KD, Blair SN, Billington C. Weight bias among health professionals specializing in obesity. Obes Res. 2003;11(9):1033-1039. [DOI] [PubMed]
  • 65.Sabin JA, Marini M, Nosek BA. Implicit and explicit anti-fat bias among a large sample of medical doctors by BMI, race/ethnicity and gender. PLoS ONE. 2012;7(11):e48448. [DOI] [PMC free article] [PubMed]
  • 66.Pearl RL, Puhl RM. Weight bias internalization and health: a systematic review. Obes Rev. 2018;19(8):1141-1163. [DOI] [PMC free article] [PubMed]
  • 67.Puhl RM, Himmelstein MS, Quinn DM. Internalizing weight stigma: prevalence and sociodemographic considerations in US adults. Obesity (Silver Spring). 2018;26(1):167-175. [DOI] [PubMed]
  • 68.Puhl RM, Phelan SM, Nadglowski J, Kyle TK. Overcoming weight bias in the management of patients with diabetes and obesity. Clin Diabetes. 2016;34(1):44-50. [DOI] [PMC free article] [PubMed]
  • 69.Puhl RM. What words should we use to talk about weight? A systematic review of quantitative and qualitative studies examining preferences for weight-related terminology. Obes Rev. 2020;21(6):e13008. [DOI] [PubMed]
  • 70.Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-weight fluctuations and outcomes in coronary disease. N Engl J Med. 2017;376(14):1332-1340. [DOI] [PubMed]
  • 71.Oh TJ, Moon JH, Choi SH, et al. Body-weight fluctuation and incident diabetes mellitus, cardiovascular disease, and mortality: a 16-year prospective cohort study. J Clin Endocrinol Metab. 2019;104(3):639-646. [DOI] [PubMed]
  • 72.Lissner L, Odell PM, D'Agostino RB, et al. Variability of body weight and health outcomes in the Framingham population. N Engl J Med. 1991;324(26):1839-1844. [DOI] [PubMed]

Articles from Journal of General Internal Medicine are provided here courtesy of Society of General Internal Medicine

RESOURCES